X

Drug Profile

L 873724

Alternative Names: Cathepsin K inhibitor - Celera Group/Merck; L-873724

Latest Information Update: 30 Jan 2008

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Celera Genomics Group
Class Osteoporosis therapies; Small molecules
Mechanism of Action Bone resorption factor inhibitors; Cathepsin K inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Postmenopausal osteoporosis

Most Recent Events

31 Aug 2006 Preclinical findings have been added to the pharmacokinetics and Women's Health pharmacodynamics sections ,
26 Jul 2004 Phase-I clinical trials in Postmenopausal osteoporosis in USA (PO)
04 Dec 2001 Axys Pharmaceuticals has been acquired by Celera Genomics Group

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com